Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Rapport Therapeutics, Inc. ( RAPP ) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania September 22, 2026 12:30 PM EDT Company Participants Abraham Ceesay - CEO, President, Treasurer & Director Jeffrey Sevigny - Chief Medical Officer Conference Call Participants Mauricio Tohen Gary Sachs Lydia Erdman - Goldman Sachs Group, Inc., Research Division John Cox - Jefferies LLC, Research Division Joseph Thome - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Kambiz Yazdi - BTIG, LLC, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Presentation Operator Welcome to the Rapport Therapeutics KOL call on Bipolar Mania and Rapport's RAP-219 clinical program. [Operator Instructions] During this call, management will make forward-looking statements, including related to its Phase II trial of RAP-219 in bipolar mania as well as the timing of data, the company's development plans and the potential commercial opportunity for RAP-219. Actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties caused by factors described in the company's securities filings. Rapport undertakes no duty or obligation to update any forward-looking statements. Rapport sponsors this presentation. Any opinions identified as those of the key opinion leaders reflect their independent clinical and scientific judgment and do not necessarily represent the views of their employer or affiliated institutions. Information is current as of September 22, 2026. Do not record, reproduce or distribute this presentation without prior written permission. I will now turn the call over to Abe Ceesay, Chief Executive Officer of Rapport Therapeutics. Please go ahead, Abe. Abraham Ceesay CEO, President, Treasurer & Director Good afternoon, everyone, and thanks for joining us today. My name is Abe Ceesay, Chief Executive Officer of Rapport Therapeutics. To help provide context for the bipolar mania